Windtree Therapeutics
WINT
WINT was delisted on the 20th of August, 2025.
4 hedge funds and large institutions have $390K invested in Windtree Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
7,908% more capital invested
Capital invested by funds: $4.87K → $390K (+$385K)
300% more funds holding
Funds holding: 1 → 4 (+3)
0.2% more ownership
Funds ownership: 0.01% → 0.2% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$948K |
| 2 |
Morgan Stanley
New York
|
+$22.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.72K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.42K |
Top Sellers
WINT Hedge Fund Activity: Q3 2024 in Review
4 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q3 2024, worth a combined $390K — up 7,908% from $4.87K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new WINT positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $948K.
- 4 institutional investors held Windtree Therapeutics (WINT) as of Q3 2024, up from 1 in Q2 2024.
- Funds reported $390K of Windtree Therapeutics stock for Q3 2024, up 7,908% quarter-over-quarter.
- 3 funds opened new Windtree Therapeutics positions in Q3 2024 and 0 closed out, a net change of +3 holders.
- The largest Windtree Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $948K added.
Based on aggregated 13F filings for Q3 2024.